<Disease><Name>FAZIO-LONDE SYNDROME</Name><Synonym>BULBAR PALSY, PROGRESSIVE, OF CHILDHOOD</Synonym><OMIM><Number>211500</Number><URL>http://omim.org/entry/211500</URL></OMIM><Orphanet><Number>56965</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=56965</URL></Orphanet><Protein><Number>Solute carrier family 52, riboflavin transporter, member 3</Number><URL>https://www.uniprot.org/uniprot/Q9NQ40</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>20p13</Gene><ICD /><Summary>very rare;autosomal recessive;mutations in the SLC52A3 gene</Summary><Symptoms><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2261</id><symptom>hyperreflexia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1787</id><symptom>muscle weakness</symptom><category>MUSCLES</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>3949</id><symptom>pontobulbar palsy</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>1773</id><symptom>ptosis (drooping eyelid)</symptom><category>EYES</category></symtomp><symtomp><id>2143</id><symptom>respiratory insufficiency / respiratory failure</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>2142</id><symptom>swallowing difficulties</symptom><category>GASTROINTESTINAL SYSTEM | GASTROINTESTINAL SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>1615</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>1.20</min><max>5.80</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1808</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>20.00</min><max>42.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1811</id><name>Glutaric acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>67.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>495</id><name>Dicarboxylic acids</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>0.00</max><unit>traces</unit><age>child</age><method /><comment /></metabolite><metabolite><id>1121</id><name>Dicarboxylic acids</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>0.00</max><unit>traces</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>445</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method /><comment /></metabolite><metabolite><id>614</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>19.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>615</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>11.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>616</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>15.00</max><unit>mmol/mol creatinine</unit><age>childhood 4-6y</age><method /><comment /></metabolite><metabolite><id>617</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>1.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>618</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>normal/inc</value><min>2.00</min><max>10.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>56</id><name>Glutaric acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.70</min><max>3.60</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>551</id><name>Glutaric acid</name><specimen>urine</specimen><value>normal/inc</value><min>3.00</min><max>19.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>552</id><name>Glutaric acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>15.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>553</id><name>Glutaric acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>554</id><name>Glutaric acid</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>284</id><name>Glutaric acid</name><specimen>plasma</specimen><value>normal/inc</value><min>0.50</min><max>2.90</max><unit>&#956;mol/l</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>360</id><name>Glutaric acid</name><specimen>cerebrospinal fluid</specimen><value>normal/inc</value><min>0.18</min><max>0.63</max><unit>&#956;mol/l</unit><age>ALL</age><method>GCMS</method><comment /></metabolite></Metabolites><Literatures><literature><id>6519</id><title>Fazio-Londe syndrome in siblings from India with different phenotypes</title><author>Gowda VK,</author><journal>Brain Dev</journal><year>2018</year><book /><volume>40</volume><number>7</number><pages>582-586</pages><co_aut>et al</co_aut></literature><literature><id>6520</id><title>Early onset of Fazio-Londe syndrome: the first case report from the Arabian Peninsula</title><author>Hossain MA,</author><journal>Hum Genome Var</journal><year>2017</year><book /><volume>4</volume><number>0</number><pages>17018</pages><co_aut>et al.</co_aut></literature><literature><id>6521</id><title>Fazio Londe syndrome: A treatable disorder</title><author>Varadarajan P,</author><journal>Ann Indian Acad Neurol</journal><year>2015</year><book /><volume>18</volume><number>1</number><pages>87-89</pages><co_aut>Thayanathi V, Pauline LC</co_aut></literature><literature><id>6522</id><title>The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives</title><author>Bosch AM,</author><journal>Orphanet J Rare Dis</journal><year>2012</year><book /><volume>7</volume><number>0</number><pages>83</pages><co_aut>et al.</co_aut></literature><literature><id>6523</id><title>Brown-Vialetto-Van Laere and Fazio Londe syndromes: defects of riboflavin transport with biochemical similarities to multiple a</title><author>Bennett MJ.</author><journal>J Inherit Metab Dis</journal><year>2012</year><book /><volume>35</volume><number>6</number><pages>941-942</pages><co_aut /></literature><literature><id>6524</id><title>Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a clinical, biochemical and genetic study</title><author>Ciccolella M,</author><journal>Neuromuscul Disord</journal><year>2012</year><book /><volume>22</volume><number>12</number><pages>1075-1082</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>